Tirzepatide is a dual agonist that primarily targets: GLP-1 receptors GIP receptors Research interest around Tirzepatide largely focuses on: appetite signaling metabolic regulation glucose response pathways body composition research Because it interacts with two incretin pathways simultaneously, Tirzepatide became one of the most widely discussed next-generation peptide compounds in metabolic research
Implications for telehealth and wellness brands: Telehealth platforms including Hims & Hers and Noom have been preparing for this, acquiring compounding facilities with plans to produce and offer peptides to consumers
Moderate damage/restoration: 500-750 mcg daily (split into 2-3 doses), lasting 4 weeks, then reduce to 250 mcg
EBioMedicine 40:554-563
A: Guanjie Biotech supplies 98% pure GHK-Cu Copper Tripeptide-1 Powder, a blue crystalline peptide raw material designed for cosmetic and beauty applications
This work was funded by the National Heart, Lung and Blood Institute (R01HL095388 to AS and MEL), National Center for Advancing Translational Science (UL1 TR000157 to AS and MEL), National Science Foundation (Integrative Graduate Education and Research Traineeship to JDC and JEZ), British Columbia Lung Association, Canadian Institute for Health Research, Parker B Francis Foundation (Senior Fellowship to TLH) and the Dutch Asthma Foundation and European Respiratory Society (International Research Fellowship to CAB)